bioAffinity Closes $4M At-the-Market Private Placement Amid Nasdaq Delisting Fight
BIAF sits 20% above its 52-week low of $0.325 on light trading volume (0.3× avg).
Summary
bioAffinity Technologies closed a $4M private placement of pre-funded warrants priced at-the-market under Nasdaq rules. The deal includes warrants exercisable at $0.4727 after stockholder approval, expiring in five years. This follows the Nasdaq delisting notice for failing the $1 minimum bid price rule and a going concern warning with cash runway ending this month. The capital injection is modest relative to the company's $3.15M market cap and provides near-term liquidity, but the at-the-market pricing reflects the stock's depressed level. Watch for stockholder approval of warrant exercise and any reverse split proposal to regain Nasdaq compliance.
At the time of this announcement, BIAF was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.33 to $13.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.